NCT05040659Active, not recruiting
Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2
Source: ClinicalTrials.gov · Last updated 6 Mar 2026
Brief summary (registry, in English)
The purpose of this study is to learn more about how to better track smell recovery in people who have been infected with the SARS-CoV-2 virus (which causes COVID-19). Many people who have been infected by this virus develop changes in their sense of smell (olfaction). We are interested in measuring smell function objectively via smell cards that test odor intensity, identification, and discrimination. Objective and precise olfactory testing that can be performed in the convenience of one's home will help identify people with smell loss after infection by SARS-CoV-2. We will use results from this test to better understand the relationship between SARS-CoV-2 infection and recovery of olfactory function and to learn whether the AROMHA longitudinal smell test is a reliable olfactory function tracking tool to quantify smell loss in the context of COVID infection. These results may inform the design of therapeutic clinical trials to accelerate the recovery of smell function.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 1000 (estimated)
- First submitted
- 18 Aug 2021
- Start date
- 14 Nov 2022
- Primary completion date
- 30 Dec 2024
- Lead sponsor
- Massachusetts General Hospital
- Diseases
- Long COVID and ME/CFS
- NCT number
- NCT05040659
What you commit to
- Study type: Observational
- Planned participants: 1000
- From 14 Nov 2022 to the primary completion date, 30 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- For participants with COVID-19-related smell loss:
Other
- 1\. Known odor-evoked adverse effects, e.g. asthma.
- For asymptomatic participants:
- 1\. Known odor-evoked adverse effects, e.g. asthma.
- 1\. Known odor-evoked adverse effects, e.g. asthma.
Who the study is looking for
- Known anosmia (for anosmic patients only)
- Age greater than or equal to 18
- Access to phone, tablet or computer connected to the internet.
- No symptoms of COVID infection at the time of enrollment.
- Age greater than or equal to 18
- Access to phone, tablet or computer connected to the internet.
- Past infection of SARS-CoV-2 virus as validated by a previous PCR or antigen test
- Age greater than or equal to 18
- Access to phone, tablet or computer connected to the internet.
Criteria the registry did not label
- For anosmic patients/healthy controls:
Age in the registry: 18 years to 100 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Massachusetts General Hospital Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.